LIFECORE BIOMEDICAL, INC. Deferred Tax Liabilities, Unrealized Gains on Trading Securities
LIFECORE BIOMEDICAL, INC. (LFCR) had Deferred Tax Liabilities, Unrealized Gains on Trading Securities of $0 as of 2022-05-29, per its 10-K/A filed 2023-03-16.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities · last filed 2024-03-20
- 2022-05-29: Deferred Tax Liabilities, Unrealized Gains on Trading Securities $0.00.
- 2021-05-30: Deferred Tax Liabilities, Unrealized Gains on Trading Securities $1.38M.
- 2020-05-31: Deferred Tax Liabilities, Unrealized Gains on Trading Securities $3.44M.
- 2019-05-26: Deferred Tax Liabilities, Unrealized Gains on Trading Securities $4.40M.
| Period end | Deferred Tax Liabilities, Unrealized Gains on Trading Securities |
|---|---|
| 2022-05-29 | $0.00 10-K/A · filed 2023-03-16 |
| 2021-05-30 | $1.38M 10-K · filed 2024-03-20 |
| 2020-05-31 | $3.44M 10-K · filed 2021-07-29 |
| 2019-05-26 | $4.40M 10-K · filed 2020-08-14 |
| 2018-05-27 | $3.72M 10-K · filed 2019-08-01 |
| 2017-05-28 | $11.49M 10-K · filed 2018-08-09 |
| 2016-05-29 | $11.13M 10-K/A · filed 2018-03-15 |
| 2015-05-31 | $10.75M 10-K · filed 2016-08-01 |
| 2014-05-25 | $9.27M 10-K · filed 2015-07-31 |
| 2013-05-26 | $5.50M 10-K · filed 2014-08-01 |
| 2012-05-27 | $2.51M 10-K · filed 2013-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |